2023
Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
Kim I. Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT. Investigative And Clinical Urology 2023, 64: 310-311. PMID: 37417555, PMCID: PMC10330420, DOI: 10.4111/icu.20230178.Peer-Reviewed Original ResearchMeSH KeywordsEarly Detection of CancerHumansMaleMass ScreeningProstate-Specific AntigenProstatic Neoplasms
2022
Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve
Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve. Journal Of Endourology 2022, 36: 1285-1289. PMID: 35906798, PMCID: PMC9587764, DOI: 10.1089/end.2021.0885.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyShort-term outcomesCase seriesRadical prostatectomyAcceptable short-term outcomesSurgeon 2Average prostate weightLearning curveMedian patient ageClavien-Dindo scaleMedian operating timeTotal postoperative complicationsShorter hospital stayLarge case seriesOperating timeProstate-specific antigenRobotic radical prostatectomyInstitutional review boardSignificant learning curveHospital stayMedian followPostoperative complicationsIntraoperative complicationsPerioperative outcomesBlood lossUntargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome
Ma Y, Zheng Z, Xu S, Attygalle A, Kim I, Du H. Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome. Analyst 2022, 147: 3043-3054. PMID: 35642979, DOI: 10.1039/d2an00676f.Peer-Reviewed Original ResearchMeSH KeywordsAtmospheric PressureHumansMaleMass SpectrometryMetabolomicsProstatic NeoplasmsTreatment OutcomeConceptsAtmospheric pressure chemical ionization mass spectrometryPressure chemical ionization mass spectrometryChemical ionization mass spectrometryMass spectrometryLaser diode thermal desorptionIonization mass spectrometryMass/charge ratioMass spectroscopyChemical profilingBackbone fragmentsCharge ratioThermal desorptionSpectrometryMetabolite profilingPeak intensityUrine metabolite profilingUrine samplesSpectroscopyIonsDesorptionHereinUrine metabolitesMultivariate statistical analysis
2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAndrogen AntagonistsHumansMaleMiddle AgedNeoplasm MetastasisProstatic NeoplasmsSurvival AnalysisYoung AdultConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsComparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical prostatectomyAssisted radical prostatectomyConsole timeRadical prostatectomyPrimary treatmentStereotactic body radiation therapyFeasible salvage optionNonsurgical primary treatmentPostoperative pad useUrinary function outcomesRisk of incontinenceKaplan-Meier curvesBody radiation therapyProportional hazards modelLonger console timeT-testStudent's t-testPostoperative complicationsMedian followupOncologic outcomesPerioperative dataBlood lossComplication rateSalvage optionFunction outcomesRelationship communication and the course of psychological outcomes among couples coping with localised prostate cancer
Manne S, Kashy D, Myers‐Virtue S, Zaider T, Kissane D, Heckman C, Kim I, Penedo F, Lee D. Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer. European Journal Of Cancer Care 2021, 30: e13401. PMID: 33586282, PMCID: PMC9165020, DOI: 10.1111/ecc.13401.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalCommunicationEmotional AdjustmentHumansInterpersonal RelationsMaleProstatic NeoplasmsSpousesConceptsBetter psychological outcomesPsychological outcomesPoor psychological outcomesRelationship communicationCancer-specific distressMeasures of communicationMutual avoidancePsychological adjustmentCommunication variablesCommunication trainingCancer concernsEffective interventionsGood communicationDepressive symptomsHigher disclosureProstate cancerImportant predictorPredictive rolePositive standingAvoidancePositive directionProstate cancer patientsSpousesMore researchGreater focus
2020
Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture
Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture. Nutrition And Cancer 2020, 73: 2740-2750. PMID: 33319628, PMCID: PMC8670097, DOI: 10.1080/01635581.2020.1857412.Peer-Reviewed Original ResearchMeSH KeywordsAlpha-TocopherolAnimalsDietary SupplementsGamma-TocopherolHumansMaleProstateProstatic NeoplasmsTocopherolsVitamin EConceptsVitamin E mixtureProstate tissue levelsUrine samplesReported adverse eventsDay of surgeryProstate cancer patientsPhase 0 trialsDays of supplementationCancer preventive activityAdverse eventsBlood lossTreatment armsUrine levelsCancer patientsRadical prostatectomyAnimal modelsVitamin EProstate tissueTissue levelsPreventive activitiesProstate levelsSupplementationPatientsProstatectomySurgeryTherapeutic prognosis of prostate cancer using surface‐enhanced Raman scattering of patient urine and multivariate statistical analysis
Ma Y, Chi J, Zheng Z, Attygalle A, Kim I, Du H. Therapeutic prognosis of prostate cancer using surface‐enhanced Raman scattering of patient urine and multivariate statistical analysis. Journal Of Biophotonics 2020, 14: e202000275. PMID: 32909380, DOI: 10.1002/jbio.202000275.Peer-Reviewed Original ResearchAbrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation
Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation. Cancer 2020, 126: 5114-5123. PMID: 32888321, DOI: 10.1002/cncr.33179.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceProstate cancerSurvival disparitiesWhite menProstate cancer screening recommendationsBlack menPCa-specific survivalAdverse clinical featuresCancer screening recommendationsEnd Results (SEER) databaseYear of diagnosisProstate-specific antigenClinical featuresScreening recommendationsResults databaseSurvival outcomesGrade CGrade D.White individualsMenRacial discrepanciesSurvivalTask ForceOutcomesTotalThe cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchMeSH KeywordsCytoreduction Surgical ProceduresHumansMaleProstateProstatectomyProstatic NeoplasmsRandomized Controlled Trials as TopicTreatment OutcomeConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithmIndividual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasis
2019
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
Lee G, Rosenfeld J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLOS ONE 2019, 14: e0213488. PMID: 31536510, PMCID: PMC6752758, DOI: 10.1371/journal.pone.0213488.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBeta CateninCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmHumansMaleMiceMice, KnockoutNeuroendocrine CellsNitrilesPhenylthiohydantoinProstatic NeoplasmsProtein BindingProtein TransportTranscription Factor 7-Like 2 ProteinXenograft Model Antitumor AssaysConceptsCastration-resistant prostate cancerEnzalutamide resistanceTranscription factor 4Neuroendocrine differentiationProstate cancerSecond-generation androgen receptor antagonistHuman prostate cancer cell linesLNCaP human prostate cancer cell lineResistant prostate cancerProstate cancer cell linesStandard of careAndrogen receptor antagonistMouse xenograft modelExpression levelsCell linesTCF4 overexpressionCancer cell linesMedian timeClinical benefitReceptor antagonistNeuroendocrine markersMetastatic CaPTreatment resistanceXenograft modelParental cell lineDihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL
Lee G, Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. Endocrinology 2019, 160: 2049-2060. PMID: 31184711, PMCID: PMC6691685, DOI: 10.1210/en.2019-00367.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyCell linesHuman peripheral blood monocytesMetastatic prostate cancerPotential treatment optionPeripheral blood monocytesCytotoxicity of macrophagesHuman monocyte cell lineProstate cancer cellsCaP cell linesMonocyte cell lineVivo mouse studiesCytotoxic activityMurine macrophage cell lineApoptosis-inducing ligandConcentration-dependent mannerDeprivation therapyClodronate liposomesTreatment optionsM1 polarizationCaP tumorsAndrogen receptorMacrophage cell lineProstate cancerImmune responseSimilar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerDDR pathway alterationProstate cancerPathway alterationsMetastatic castration-resistant prostate cancerSerum prostate-specific antigenHigh-risk diseaseMetastatic prostate cancerLower overall survivalPathway gene mutationsProstate-specific antigenPotential therapeutic targetUnited States National Cancer InstituteNational Cancer InstituteCRPC patientsCancer Genome AtlasOverall survivalSimilar incidenceTumor stageUnivariate analysisCancer InstituteTherapeutic targetSpecific antigenPARP inhibitorsPathway statusReply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? Cancer 2019, 125: 2318-2320. PMID: 30861093, DOI: 10.1002/cncr.32054.Peer-Reviewed Original ResearchCouple‐focused interventions for men with localized prostate cancer and their spouses: A randomized clinical trial
Manne S, Kashy D, Zaider T, Kissane D, Lee D, Kim I, Heckman C, Penedo F, Murphy E, Virtue S. Couple‐focused interventions for men with localized prostate cancer and their spouses: A randomized clinical trial. British Journal Of Health Psychology 2019, 24: 396-418. PMID: 30852854, PMCID: PMC8279429, DOI: 10.1111/bjhp.12359.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalCouples TherapyHumansMaleMiddle AgedPersonal SatisfactionProstatic NeoplasmsQuality of LifeSpousesConceptsCouple-focused interventionsRelationship satisfactionPsychological adjustmentCancer-specific distressPsychological adaptationRelationship communicationWellness interventionsStatement of contributionTraditional masculine normsUsual careLocalized prostate cancerRandomized clinical trialsPsychological functioningPsychological treatmentRelationship outcomesAssessment time pointsElevated distressProstate cancerLong relationshipRelationship lengthClinical trialsGeneral healthIntervention benefitsCancer concernsShorter relationships
2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh riskInterpersonal Processes and Intimacy Among Men With Localized Prostate Cancer and Their Partners
Manne S, Kashy D, Zaider T, Lee D, Kim I, Heckman C, Penedo F, Kissane D, Virtue S. Interpersonal Processes and Intimacy Among Men With Localized Prostate Cancer and Their Partners. Journal Of Family Psychology 2018, 32: 664-675. PMID: 29771551, PMCID: PMC6072581, DOI: 10.1037/fam0000404.Peer-Reviewed Original ResearchConceptsCancer-related concernsActor-partner interdependence modelInterpersonal process modelRelational intimacyPartner responsivenessRelationship intimacyDistressed couplesPartner disclosureMeasures of selfCancer-specific distressPossible moderating effectIntimacy processPartner effectsInterdependence modelModerating effectSpouse ratingsCancer concernsIndirect effectsProcess modelIntimacySelfRatingsCouplesDistressPresent study
2017
Can Genomic Data Guide the Postoperative Management of Prostate Cancer?
Parikh R, Kim I. Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Journal Of Clinical Oncology 2017, 35: jco.2017.72.484. PMID: 28471706, DOI: 10.1200/jco.2017.72.4849.Peer-Reviewed Original ResearchIntracrine androgen biosynthesis in renal cell carcinoma
Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Ahn H, Kim W, Kim I. Intracrine androgen biosynthesis in renal cell carcinoma. British Journal Of Cancer 2017, 116: 937-943. PMID: 28253524, PMCID: PMC5379152, DOI: 10.1038/bjc.2017.42.Peer-Reviewed Original ResearchMeSH KeywordsAbiraterone AcetateAndrogensAnimalsAntineoplastic AgentsApoptosisBenzamidesBlotting, WesternCarcinoma, Renal CellCell ProliferationDihydrotestosteroneFemaleHumansImmunoenzyme TechniquesKidney NeoplasmsMaleMiceMice, NudeNitrilesOrchiectomyPhenylthiohydantoinPrognosisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReal-Time Polymerase Chain ReactionReceptors, AndrogenReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTestosteroneTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsRenal cell carcinomaCastration-resistant prostate cancerRCC cell linesAnti-androgen therapyHuman RCC cell linesAndrogen biosynthesisAbiraterone acetateCell carcinomaAndrogen receptorTumor volumeCell linesAndrogen deprivation therapyHigher tumor stageProstate cancer patientsMouse xenograft studiesGenitourinary cancersTumor suppressionSignificant tumor suppressionRCC patientsTumor stageCancer patientsMale miceProstate cancerIntratumoral steroidogenesisXenograft studies